FDA Clearance Tracker · P200026-S005
Abre Venous Self-expanding Stent System
Last checked: Nov 20, 2026Latest source record: Jul 22, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jul 22, 2022
Approved
Time to decision
35 days
Received Jun 17, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P200026-S005
- Device name
- Abre Venous Self-expanding Stent System
- Applicant
- Medtronic Vascular, Inc.
- Applicant location
- Plymouth, MN
- Received
- Jun 17, 2022
- Decided
- Jul 22, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P200026
Device type
- Device type
- Stent, iliac vein (QAN)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for updates to the labeling to include long-term results from the ABRE Continued Follow-Up Study.
Source documents
Other decisions for Medtronic Vascular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K202800 · Decided Nov 18, 2020 · 56 days after receipt
Device type: Catheter, Angioplasty, Peripheral, Transluminal (LIT) · Cardiology
P200026 · Decided Oct 21, 2020 · 177 days after receipt
Device type: Stent, iliac vein (QAN) · Cardiology
P190008 · Decided Nov 21, 2019 · 232 days after receipt
Device type: Drug-coated peripheral transluminal angioplasty catheter (PRC) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.